200 related articles for article (PubMed ID: 32853135)
1. Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists.
Hotte SJ; Finelli A; Chi KN; Canil C; Fleshner N; Kapoor A; Kolinsky M; Malone S; Morash C; Niazi T; Noonan KL; Ong M; Pouliot F; Shayegan B; So AI; Sorabji D; Hew H; Park-Wyllie L; Saad F
Can Urol Assoc J; 2021 Feb; 15(2):E90-E96. PubMed ID: 32853135
[TBL] [Abstract][Full Text] [Related]
2. Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum.
Saad F; Canil C; Finelli A; Hotte SJ; Malone S; Shayegan B; So AI; Aaron L; Basappa NS; Conter HJ; Danielson B; Gotto G; Hamilton RJ; Izard JP; Kapoor A; Kolinsky M; Lalani AA; Lattouf JB; Morash C; Morgan SC; Niazi T; Noonan KL; Ong M; Rendon RA; Sehdev S; Hew H; Park-Wyllie L; Chi KN
Can Urol Assoc J; 2020 Apr; 14(4):E137-E149. PubMed ID: 31702544
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ekeke ON; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis C; Mahal B; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro CJ; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur J Cancer; 2023 May; 185():178-215. PubMed ID: 37003085
[TBL] [Abstract][Full Text] [Related]
4. Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide.
Bivins VM; Durkin M; Khilfeh I; Rossi C; Kinkead F; Waters D; Lefebvre P; Pilon D; Ellis L
Future Oncol; 2022 Oct; 18(32):3595-3607. PubMed ID: 36196743
[No Abstract] [Full Text] [Related]
5. Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forum.
Saad F; Hotte SJ; Noonan K; Malone S; Morash C; Niazi T; Rendon RA; Shayegan B; Basappa NS; Cagiannos I; Danielson B; Delouya G; Fernandes R; Ferrario C; Finelli A; Gotto GT; Hamilton RJ; Izard JP; Kapoor A; Lalani AK; Lavallée LT; Ong M; Pouliot F; So AI; Yip S; Chi KN
Can Urol Assoc J; 2024 Apr; 18(4):E127-E137. PubMed ID: 38381937
[TBL] [Abstract][Full Text] [Related]
6. Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers.
Saad F; Hotte SJ; Finelli A; Malone S; Niazi T; Noonan K; Shayegan B; So AI; Danielson B; Basappa NS; Cagiannos I; Canil C; Delouya G; Fernandes R; Ferrario C; Gotto GT; Hamilton RJ; Izard JP; Kapoor A; Khalaf D; Kolinsky M; Lalani AK; Lavallée LT; Morash C; Morgan SC; Ong M; Pouliot F; Rendon RA; Yip S; Zardan A; Park-Wyllie L; Chi K
Can Urol Assoc J; 2021 Oct; 15(10):353-358. PubMed ID: 34125066
[TBL] [Abstract][Full Text] [Related]
7. Management algorithms for metastatic prostate cancer.
Malone S; Shayegan B; Basappa NS; Chi K; Conter HJ; Hamilton RJ; Hotte SJ; Saad F; So AI; Park-Wyllie L; Hew H; McLeod D; Gotto G
Can Urol Assoc J; 2020 Feb; 14(2):50-60. PubMed ID: 31039111
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns.
Chiong E; Saad M; Hamid ARAH; Ong-Cornel AB; Lojanapiwat B; Pripatnanont C; Serrano D; Songco J; Sin LC; Hakim L; Chua MLK; Nguyen NP; Phuong PC; Patnaik RS; Umbas R; Kanesvaran R
Ther Adv Med Oncol; 2024; 16():17588359231216582. PubMed ID: 38249332
[TBL] [Abstract][Full Text] [Related]
9. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
[TBL] [Abstract][Full Text] [Related]
10. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
Shore N; Oliver L; Shui I; Gayle A; Wong OY; Kim J; Payne S; Amin S; Ghate S
J Urol; 2021 Apr; 205(4):977-986. PubMed ID: 33332152
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data.
Freedland SJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Ryan CJ
Curr Med Res Opin; 2021 Apr; 37(4):609-622. PubMed ID: 33476184
[TBL] [Abstract][Full Text] [Related]
12. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N
Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
[TBL] [Abstract][Full Text] [Related]
13. Managing Nonmetastatic Castration-resistant Prostate Cancer.
Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.
Barata PC; Leith A; Ribbands A; Montgomery R; Last M; Arondekar B; Ivanova J; Niyazov A
Oncologist; 2023 Sep; 28(9):e737-e747. PubMed ID: 37014097
[TBL] [Abstract][Full Text] [Related]
15. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
[TBL] [Abstract][Full Text] [Related]
16. Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice.
Bögemann M; Facchini G; Bauernhofer T; Cathomas R; Xylinas E; Tombal B
Ir J Med Sci; 2023 Dec; 192(6):2643-2651. PubMed ID: 36944842
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Shore ND; Drake CG; Lin DW; Ryan CJ; Stratton KL; Dunshee C; Karsh LI; Kaul S; Kernen K; Pieczonka C; Sieber P; Stewart C; Williams M; Concepcion RS
Prostate; 2020 Oct; 80(14):1159-1176. PubMed ID: 32779781
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients.
Sánchez JC; Picola N; Rodriguez-Vida A; Costa M; Castañeda DM; Márquez MP; Rodriguez JM; Gaya JM; Bravo A; Buisan O; Servian P; Suarez JF; Felip MM; Caparrós MJR; Asensio AA; Vilaseca A
Cancer Med; 2023 Dec; 12(24):21969-21977. PubMed ID: 38063364
[TBL] [Abstract][Full Text] [Related]
19. Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the results from the Advanced Prostate Cancer Consensus Conference.
Fujita K; Suzuki H; Hinata N; Miura Y; Edamura K; Tabata KI; Arai G; Matsubara N; Yasumizu Y; Kosaka T; Oya M; Sugimoto M
Transl Androl Urol; 2022 Dec; 11(12):1771-1785. PubMed ID: 36632151
[TBL] [Abstract][Full Text] [Related]
20. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
Mukherji D; Youssef B; Dagher C; El-Hajj A; Nasr R; Geara F; Rabah D; Al Dousari S; Said R; Ashou R; Wazzan W; Jabbour M; Farha G; Al Hamdani N; Al Hallaq Y; Ghazal H; Dbouk H; Bachir B; El Khoury C; Sakr G; Hussain HK; Sayyid K; Ibrahim K; Haidar M; Zouain N; Bitar N; Alameh W; Abbas F; Faddoul S; Nemer E; Assaf G; Farhat F; Bulbul M; Temraz S; Shamseddine A; Gillessen S; Omlin A; Khauli R
World J Urol; 2020 Mar; 38(3):681-693. PubMed ID: 31297628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
